alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                           FEB-1-1997
<PERIOD-START>                              FEB-4-1996
<PERIOD-END>                                NOV-2-1996
<CASH>                                          58,823
<SECURITIES>                                         0
<RECEIVABLES>                                  204,883
<ALLOWANCES>                                    10,133
<INVENTORY>                                    309,911
<CURRENT-ASSETS>                               586,007
<PP&E>                                         102,601
<DEPRECIATION>                                  45,610
<TOTAL-ASSETS>                                 745,999
<CURRENT-LIABILITIES>                          536,255
<BONDS>                                              0
<PREFERRED-MANDATORY>                              250
<PREFERRED>                                          0
<COMMON>                                           409
<OTHER-SE>                                     121,994
<TOTAL-LIABILITY-AND-EQUITY>                   745,999
<SALES>                                      2,612,988
<TOTAL-REVENUES>                             2,612,988
<CGS>                                        2,491,081
<TOTAL-COSTS>                                2,491,081
<OTHER-EXPENSES>                               212,814
<LOSS-PROVISION>                                 3,944
<INTEREST-EXPENSE>                              10,043
<INCOME-PRETAX>                              (105,422)
<INCOME-TAX>                                   (6,532)
<INCOME-CONTINUING>                           (98,900)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (98,900)
<EPS-PRIMARY>                                   (2.79)
<EPS-DILUTED>                                   (2.79)
        

</TABLE>
# C_2015155EN.01004003.xml

| 11.5.2015 | EN | Official Journal of the European Union | C 155/40 |
| --- | --- | --- | --- |

11.5.2015

EN

Official Journal of the European Union

C 155/40

---

Order of the General Court of 16 March 2015 — Mat Foundries Europe v Commission

(Case T-309/14) (1)

1

(2015/C 155/57)

Language of the case: German

The President of the Third Chamber has ordered that the case be removed from the register.

---

(1)  OJ C 223, 14.7.2014.

1

---
# W.S. Dodge OilCo, Inc. 3710 FruitlandAvenue Maywood, California 90270 (323) 583-3478 • www.wsdodgeoil.com • FAX(323) 583-0950

August 27, 2013 Mr. Stan Cowen, Air Quality Engineer Ventura County Air Pollution Control District 669 County Square Drive Ventura, CA 93003 Re : Rule 74.31 -Metalworking Fluids and Direct Contact Lubricants Dear Mr. Cowen: The W.S. Dodge Company ("Dodge") is pleased to fully endorse the adoption of Rule 74.31 -Metalworking Fluids and Direct Contact Lubricants. Dodge is the largest provider of metalworking fluids in the Greater Southern California area, including Ventura County. We are in our 52nd year offamily owned operation. Our offerings run the full range of cutting, grinding, forming, forging, heat treating, and rust protecting fluids. Dodge also worked tirelessly with the South Coast Air Quality Management District on their Rule 1144. We believe Rule 74.31, which closely follows SCAQMD Rule 1144, is an outstanding example ofsimultaneously protecting our environment while allowing manufacturers to continue to prosper. Ifyou have any further questions, please call or write. We look forward to assisting VCAPCD in the implementation of 74.31.

Thomas 

### J. Downs President

www. wsdodgeoil.com
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.3125 *Citrobacter* spp. serological reagents. ( a ) *Identification. Citrobacter* spp. serological reagents are devices that consist of antigens and antisera used in serological tests to identify *Citrobacter* spp. from cultured isolates derived from clinical specimens. The identification aids in the diagnosis of disease caused by bacteria belonging to the genus *Citrobacter* and provides epidemiological information on diseases caused by these microorganisms. *Citrobacter* spp. have occasionally been associated with urinary tract infections.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 54 FR 25046, June 12, 1989; 66 FR 38791, July 25, 2001]
Editorial Note on Part 73
Editorial Note: Nomenclature changes to part 73 appear at 66 FR 66742, Dec. 27, 2001.

§ 73.2329 Guanine. ( a ) *Identity and specifications.* ( 1 ) The color additive guanine shall conform in identity and specifications to the requirements of § 73.1329 (a)(1) and (b).
( 2 ) Color additive mixtures of guanine may contain the following diluents: ( i ) For coloring cosmetics generally, only those diluents listed under § 73.1001(a)(1);
( ii ) For coloring externally applied cosmetics, only those diluents listed in § 73.1001(b) and, in addition, nitrocellulose.
( b ) *Use and restrictions.* The color additive guanine may be safely used in cosmetics generally, including cosmetics intended for use in the area of the eye, in amounts consistent with good manufacturing practice.
( c ) *Labeling requirements.* The color additive and any mixtures prepared therefrom intended solely or in part for coloring purposes shall bear, in addition to any information required by law, labeling in accordance with the provisions of § 70.25 of this chapter.
( d ) *Exemption from certification.* Certification of this color additive is not necessary for the protection of the public health, and therefore batches thereof are exempt from the certification pursuant to section 721(c) of the act.
[42 FR 37537, July 22, 1977]
§ 74.1336 D&C Red No. 36. ( a ) *Identity.* ( 1 ) The color additive D&C Red No. 36 is 1-[(2-chloro-4-nitrophenyl)azo]-2-naphthalenol (CAS Reg. No. 2814-77-9). The color additive is manufactured by diazotization of 2-chloro-4-nitrobenzenamine in acid medium and coupling with 2-naphthalenol in acid medium.
( 2 ) Color additive mixtures for drug use made with D&C Red No. 36 may contain only those diluents that are suitable and that are listed in part 73 of this chapter as safe for use in color additive mixtures for coloring drugs.
( b ) *Specifications.* D&C Red No. 36 shall conform to the following specifications and shall be free from impurities other than those named to the extent that such impurities may be avoided by current good manufacturing practice: Volatile matter at 135 °C (275 °F), not more than 1.5 percent. Matter insoluble in toluene, not more than 1.5 percent. 2-Chloro-4-nitrobenzenamine, not more than 0.3 percent. 2-Naphthalenol, not more than 1 percent. 2,4-Dinitrobenzenamine, not more than 0.02 percent. 1-[(2,4-Dinitrophenyl)azo]-2-naphthalenol, not more than 0.5 percent. 4-[(2-Chloro-4-nitrophenyl)azo]-1-naphthalenol, not more than 0.5 percent. 1-[(4-Nitrophenyl)azo]-2-naphthalenol, not more than 0.3 percent. 1-[(4-Chloro-2-nitrophenyl)azo]-2-naphthalenol, not more than 0.3 percent. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million. Mercury (as Hg), not more than 1 part per million. Total color, not less than 95 percent.
( c ) *Uses and restrictions.* The color additive D&C Red No. 36 may be safely used for coloring ingested drugs, other than mouthwashes and dentifrices, in amounts not to exceed 1.7 milligrams per daily dose of the drug for drugs that are taken continuously only for less than 1 year. For drugs taken continuously for longer than 1 year, the color additive shall not be used in amounts to exceed 1.0 milligram per daily dose of the drug. D&C Red No. 36 may be safely used for coloring externally applied drugs in amounts consistent with current good manufacturing practice.
( d ) *Labeling requirements.* The label of the color additive and any mixtures prepared therefrom intended solely or in part for coloring purposes shall conform to the requirements of § 70.25 of this chapter.
( e ) *Certification.* All batches of D&C Red No. 36 shall be certified in accordance with regulations in part 80 of this chapter.
[53 FR 29031, Aug. 2, 1988; 53 FR 35255, Sept. 12, 1988, as amended at 53 FR 52130, Dec. 27, 1988]
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1465 Lipase test system. ( a ) *Identification.* A lipase test system is a device intended to measure the activity of the enzymes lipase in serum. Lipase measurements are used in diagnosis and treatment of diseases of the pancreas such as acute pancreatitis and obstruction of the pancreatic duct.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
[52 FR 16122, May 1, 1987, as amended at 65 FR 2307, Jan. 14, 2000]
Order entered March 11, 2015 

In The 

Court of Appeals 

Fifth District of Texas at Dallas 

No. 05-15-00220-CV 

IN RE LUIS A. SANTIAGO, AND LINDA A. SANTIAGO, Relators 

Original Proceeding from the 219th Judicial District Court 

Collin County, Texas 

Trial Court Cause No. 296-02073-2011 

ORDER 

Based on the Court’s opinion of this date, we DENY the petition for writ of mandamus. 

We ORDER relator’s to bear the costs of this original proceeding. 

/s/ BILL WHITEHILL 

 JUSTICE
###### Editorial Note on Part 328

#### Editorial Note:

Nomenclature changes to part 328 appear at 69 FR 13717, Mar. 24, 2004.

#### § 328.1 Scope.

Reference in this part to regulatory sections of the Code of Federal Regulations are to chapter I of title 21 unless otherwise noted.
<PAGE>
                                 EXHIBIT 10.9.1

                               AMENDMENT TO LEASE

This AMENDMENT effective this 1st day of September 2002, ("Effective Date"), is
entered into by and between the 19th Avenue/Buchanan Limited Partnership, an
Arizona Limited Partnership ("Landlord") and SCHUFF STEEL COMPANY ("Schuff") for
the Leased Premises located at 619 N. Cooper Road, Gilbert, Arizona 85233.

Whereas the Landlord and Tenant agree to amend the Lease as follows:

1.    Starting September 1, 2002, the adjusted monthly rent will be reduced in
      accordance with Exhibit "A" for the term of the lease. The Landlord, may
      with thirty (30) day written notice, increase the monthly rate to the
      amount that the rent would have been prior to this Amendment for the
      remaining term of the lease.

2.    Except as modified herein, all other rights and obligations between the
      Parties remain unchanged.

In witness whereof, the parties have executed this Amendment as of the date
written above.

         19TH AVENUE/BUCHANAN LIMITED PARTNERSHIP,
         an Arizona limited partnership
         By:  /s/ Scott A. Schuff
              ------------------------------
                  General Partner


         SCHUFF STEEL COMPANY
         --------------------
         By:  /s/ Michael Hill
              ------------------------------
         Printed Name:  Michael Hill
                        --------------------
<PAGE>
                                    EXHIBIT A

<TABLE>

Schuff Steel Company                                                                    12/4/02
Facilities Rent - No Tax

<CAPTION>

                              Lease Amount
                           Before Infl. Adj.  Infl. Adj. 3/1/02                      9/01/2002
                                Monthly             2.60%        Inflation Adjusted  Reduction  Adjusted
                           -----------------  -----------------  ------------------  ---------  --------
<S>                        <C>                <C>                <C>                 <C>        <C>
420 South 19th Avenue           50,427              1,311             51,738          13,177    38,562
1841 Buchanan                   11,250                293             11,543           2,892     8,650
619 Cooper, Gilbert             28,333                737             29,070           8,931    20,139
                                ------              -----             ------          ------    ------
Total Monthly Rent              90,010              2,340             92,350          25,000    67,350
</TABLE>
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 18-6753

UNITED STATES OF AMERICA,

Plaintiff - Appellee,

v.

TORRE LARON JOHNSON, a/k/a Torre Omar Johnson,

Defendant - Appellant.

Appeal from the United States District Court for the District of Maryland, at Baltimore. 

Richard D. Bennett, District Judge. (1:11-cr-00346-RDB-2; 1:15-cv-02420-RDB; 1:17-

cv-03592-RDB)

Submitted: October 10, 2018 Decided: October 16, 2018

Before KEENAN and WYNN, Circuit Judges, and TRAXLER, Senior Circuit Judge.

Dismissed by unpublished per curiam opinion.

Torre Laron Johnson, Appellant Pro Se. Ellen Elisabeth Cobb, OFFICE OF THE 

UNITED STATES ATTORNEY, Greenbelt, Maryland, for Appellee.

Unpublished opinions are not binding precedent in this circuit.
2

PER CURIAM:

Torre Laron Johnson seeks to appeal the district court’s order dismissing as 

untimely his 28 U.S.C. § 2255 (2012) motion. The order is not appealable unless a 

circuit justice or judge issues a certificate of appealability. 28 U.S.C. § 2253(c)(1)(B) 

(2012). A certificate of appealability will not issue absent “a substantial showing of the 

denial of a constitutional right.” 28 U.S.C. § 2253(c)(2) (2012). When the district court

denies relief on the merits, a prisoner satisfies this standard by demonstrating that 

reasonable jurists would find that the district court’s assessment of the constitutional 

claims is debatable or wrong. Slack v. McDaniel, 529 U.S. 473, 484 (2000); see MillerEl v. Cockrell, 537 U.S. 322, 336-38 (2003). When the district court denies relief on 

procedural grounds, the prisoner must demonstrate both that the dispositive procedural 

ruling is debatable, and that the motion states a debatable claim of the denial of a 

constitutional right. Slack, 529 U.S. at 484-85. 

We have independently reviewed the record and conclude that Johnson has not 

made the requisite showing. Accordingly, we deny a certificate of appealability and 

dismiss the appeal. We dispense with oral argument because the facts and legal 

contentions are adequately presented in the materials before this court and argument 

would not aid the decisional process. 

DISMISSED
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
     The schedule  contains  summary financial  information  extracted from the
consolidated  financial statements  of Ladish  Co.,  Inc.  as of and for the six
months ended June 30, 1998 and is qualified in its entirety by reference to such
financial statements.
</LEGEND>
<MULTIPLIER>                                   1,000
       
<S>                                            <C>
<PERIOD-TYPE>                                  6-MOS
<FISCAL-YEAR-END>                              DEC-31-1998
<PERIOD-START>                                 JAN-01-1998
<PERIOD-END>                                   JUN-30-1998
<CASH>                                         5,417
<SECURITIES>                                   0
<RECEIVABLES>                                  35,094 
<ALLOWANCES>                                   300
<INVENTORY>                                    47,538
<CURRENT-ASSETS>                               88,076
<PP&E>                                         130,223
<DEPRECIATION>                                 (46,619)
<TOTAL-ASSETS>                                 83,604
<CURRENT-LIABILITIES>                          56,351
<BONDS>                                        4,500
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       140
<OTHER-SE>                                     61,550
<TOTAL-LIABILITY-AND-EQUITY>                   176,464
<SALES>                                        122,450
<TOTAL-REVENUES>                               122,450
<CGS>                                          102,488
<TOTAL-COSTS>                                  4,227
<OTHER-EXPENSES>                               0
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             970
<INCOME-PRETAX>                                14,394
<INCOME-TAX>                                   1,494
<INCOME-CONTINUING>                            13,440
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   13,440
<EPS-PRIMARY>                                  1.30
<EPS-DILUTED>                                  1.11
        

</TABLE>
§ 74.1321 D&C Red No. 21. ( a ) *Identity.* ( 1 ) The color additive D&C Red No. 21 is principally 2′,4′,5′,7′-tetrabromofluorescein (CAS Reg. No. 15086-94-9), and may contain smaller amounts of 2′,4′,5′-tribromofluorescein (CAS Reg. No. 25709-83-5) and 2′,4′,7′-tribromofluorescein (CAS Reg. No. 25709-84-6). The color additive is manufactured by brominating fluorescein with elemental bromine. The fluorescein is manufactured by the acid condensation of resorcinol and phthalic acid or its anhydride. The fluorescein is isolated and partially purified prior to bromination.
( 2 ) Color additive mixtures for drug use made with D&C Red No. 21 may contain only those diluents that are suitable and that are listed in part 73 of this chapter as safe for use in color additive mixtures for coloring drugs.
( b ) *Specifications.* The color additive D&C Red No. 21 shall conform to the following specifications and shall be free from impurities other than those named to the extent that such impurities may be avoided by current good manufacturing practice: Sum of volatile matter (at 135 °C) and halides and sulfates (calculated as sodium salts), not more than 10 percent. Insoluble matter (alkaline solution), not more than 0.5 percent. Phthalic acid, not more than 1 percent. 2-(3,5-Dibromo-2,4-dihydroxybenzoyl) benzoic acid, not more than 0.5 percent. 2′,4′,5′,7′-Tetrabromofluorescein, ethyl ester, not more than 1 percent. Brominated resorcinol, not more than 0.4 percent. Fluorescein, not more than 0.2 percent. Sum of mono- and dibromofluoresceins, not more than 2 percent. Tribromofluoresceins, not more than 11 percent. 2′,4′,5′,7′-Tetrabromofluorescein, not less than 87 percent. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million. Mercury (as Hg), not more than 1 part per million. Total color, not less than 90 percent.
( c ) *Uses and restrictions.* The color additive D&C Red No. 21 may be safely used for coloring drugs generally in amounts consistent with current good manufacturing practice.
( d ) *Labeling.* The label of the color additive and any mixtures prepared therefrom intended solely or in part for coloring purposes shall conform to the requirements of § 70.25 of this chapter.
( e ) *Certification.* All batches of D&C Red No. 21 shall be certified in accordance with regulations in part 80 of this chapter.
[47 FR 53846, Nov. 30, 1982]
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.5100 Nasopharyngeal airway. ( a ) *Identification.* A nasopharyngeal airway is a device used to aid breathing by means of a tube inserted into a patient's pharynx through the nose to provide a patent airway.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 868.9.
[47 FR 31142, July 16, 1982, as amended at 61 FR 1120, Jan. 16, 1996; 66 FR 38794, July 25, 2001]
§ 861.7 Contents of standards. Any performance standard established under this part will include such provisions as the Food and Drug Administration determines are necessary to provide reasonable assurance of the safety and effectiveness of the device or devices for which it is established. Where necessary to provide such assurance, a standard will address (but need not be limited to): ( a ) Performance characteristics of the device;
( b ) The design, construction, components, ingredients, and properties of the device, and its compatibility with power systems and connections to such systems;
( c ) The manufacturing processes and quality control procedures applicable to the device;
( d ) Testing of the device on either a sample or a 100-percent basis by the manufacturer, or, if it is determined that no other more practical means are available to the Food and Drug Administration to assure the conformity of the device to the standard, providing for testing by the Food and Drug Administration or a third person to ensure that the device conforms to the standard;
( e ) The publication of the results of each test or of certain tests of the device to show that the device conforms to the portions of the standard for which the test or tests were required;
( f ) Manufacturers' certification to purchasers or to the Food and Drug Administration that the device conforms to the applicable performance standard;
( g ) Restrictions on the sale and distribution of the device, but only to the extent authorized under section 520(e) of the act;
( h ) The use, and the form and content, of labeling for the proper installation, maintenance, operation, and use of the device. Among the provisions that may be required in the labeling are warnings; storage and transportation information; expiration dates; the date and place of manufacture; the results that may be expected if the device is used properly; the ranges of accuracy of diagnostic information; instructions regarding the proper care of, and the proper components, accessories, or other equipment to be used with the device; and statements concerning the appropriate patient population, for example, a statement that the device is considered safe and effective only when used by, or in the treatment of, a patient who has been tested by particular designated procedures and found to have an illness or condition for which use of the device is indicated by a person skilled in the use of the device.